16 May 2023Read more
22 Feb 2021Read more
- Per Källblad Ph.D. Chief Executive OfficerLearn More
Inspired by the possibility of improving the prospects for patients living with life-threatening conditions, we are setting the pace for years to come in the continuously evolving cancer drug development landscape. Our growing team of future-thinking scientists and development professionals are driving the advancement of multiple life-saving therapeutics into the clinic to get them to the patients that need them.Learn More
With a clear vision and focus, we are leveraging synthetic lethality vulnerabilities to meticulously develop breakthrough solutions that specifically and effectively target genetically defined cancers.Learn More
With support from purposeful, mutually beneficial investments, we deliver value to patients and stakeholders. Our historic success in lead generation using our partner-validated drug development technology offers a secure foundation for the growth and advancement of our proprietary novel therapeutics to be progressed into the clinic.Learn More
Beactica Therapeutics' CEO, Dr Per Källblad, briefly presents the investment opportunity connected to the company's transition into a clinical-stage company.
Sign up for the Beactica newsletter to receive our latest news and updates